[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537056":3},{"organization":4,"outcomesModule":7,"designInfo":25,"detailedDescription":28,"studyPopulation":29,"armGroups":30,"interventions":24,"overallOfficials":24,"centralContacts":43,"locations":49,"responsibleParty":167,"collaborators":169,"id":173,"slug":24,"hasResults":174,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":174,"sex":180,"minAge":181,"maxAge":24,"enrollmentInfo":182,"targetDuration":185,"studyType":186,"phases":24,"briefSummary":187,"conditions":188,"keywords":191,"overallStatus":52,"whyStopped":24,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":205},{"fullName":5,"class":6},"BostonGene","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":24},[9,13],{"measure":10,"description":11,"timeFrame":12},"Frequency of actionable findings","the frequency of actionable findings identified by a comprehensive (WES\u002FRNA) sequencing platform (BostonGene Tumor Portrait) in advanced cancer patients. Actionable findings will include: genomic findings such as fusions, single nucleotide variants (SNVs), insertion\u002Fdeletion alterations (indels), copy number alterations (CNAs), tumor mutational burden (TMB), microsatellite instability (MSI), frameshifts, rearrangements, gene expression levels, genome instability and loss of heterozygosity, cell counts in TME, disease molecular type, inherited pathogenic mutations, mutational signatures, and gene isoform expression.","2 years",{"measure":14,"description":15,"timeFrame":12},"Test turn-around time","the time from consent to biopsy (or archival tissue retrieval), time from receipt of biopsy to BostonGene Tumor Portrait testing results, and total time from consent to delivery of BostonGene Tumor Portrait testing resultsTumor Portrait testing",[17,21],{"measure":18,"description":19,"timeFrame":20},"Frequency of patients who receive molecularly matched therapy","the frequency of patients who receive molecularly matched therapy within 6 months of undergoing genomic testing","6 months",{"measure":18,"description":22,"timeFrame":23},"the frequency of patients who receive molecularly matched therapy within 12 months of undergoing genomic testing","12 months",null,{"allocation":24,"interventionModel":24,"interventionModelDescription":24,"primaryPurpose":24,"observationalModel":26,"timePerspective":27,"maskingInfo":24},"COHORT","PROSPECTIVE","The BEGIN Study, conducted by BostonGene and Exigent, is a prospective investigation aimed at evaluating the efficacy and feasibility of comprehensive molecular testing in advanced cancer patients within the community setting. Recent advancements in cancer treatment have led to the integration of targeted and immune-based therapies into standard practice. Recognizing the significance of genomic and molecular alterations in patient therapy selection, BostonGene has developed a high-throughput sequencing platform, the BostonGene Tumor Portrait test, which provides a comprehensive overview of tumors and their microenvironment.\n\nThe primary objectives of the study include determining the frequency of actionable findings identified by the BostonGene Tumor Portrait test, assessing the feasibility and turnaround time of comprehensive sequencing analysis, and evaluating the frequency of patient enrollment in clinical trials based on test results. Secondary objectives involve determining the frequency of patients receiving molecularly matched therapy, evaluating concordance between DNA and RNA targets, and assessing the impact of test findings on treatment decisions.\n\nThe study will involve four cohorts of patients with breast cancer, non-small cell lung cancer, melanoma, and sarcoma, each comprising 100 participants. Subjects will be identified through designated pilot sites. The study duration will be up to two years, with data collection including baseline demographics, medical history, treatment decisions, and patient outcomes.\n\nOverall, the study aims to elucidate the clinical utility of the BostonGene Tumor Portrait test in guiding treatment decisions for advanced cancer patients in real-world community settings, with a focus on actionable findings, treatment efficacy, and patient outcomes.","Advanced cancer patients",[31,34,37,40],{"label":32,"type":24,"description":33,"interventionNames":24},"Breast cancer","Patients with locally recurrent, unresectable or metastatic breast cancer",{"label":35,"type":24,"description":36,"interventionNames":24},"NSCLC","Patients with unresectable stage III or metastatic non-small cell lung cancer",{"label":38,"type":24,"description":39,"interventionNames":24},"Melanoma","Patients with unresectable or metastatic melanoma",{"label":41,"type":24,"description":42,"interventionNames":24},"Sarcoma","Patients with locally advanced or metastatic sarcoma",[44],{"name":45,"role":46,"phone":47,"phoneExt":24,"email":48},"Rheanna Carter, MBA","CONTACT","650-773-0771","rheanna.carter@bostongene.com",[50,71,87,103,119,135,151],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Highlands Oncology Group","RECRUITING","Rogers","Arkansas","72758","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-94.11854,36.33202,{"lat":62,"lon":61},[65,68],{"name":66,"role":46,"phone":24,"phoneExt":24,"email":67},"Adam Torres","ATorres@hogonc.com",{"name":69,"role":70,"phone":24,"phoneExt":24,"email":24},"Eric Schaefer, MD","PRINCIPAL_INVESTIGATOR",{"facility":72,"status":52,"city":73,"state":74,"zip":75,"country":56,"countryCode":57,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Stockton Hematology Oncology Medical Group","Stockton","California","95204",{"type":59,"coordinates":77},[78,79],-121.29078,37.9577,{"lat":79,"lon":78},[82,85],{"name":83,"role":46,"phone":24,"phoneExt":24,"email":84},"Lizbeth Ortiz","lortiz@shomg.net",{"name":86,"role":70,"phone":24,"phoneExt":24,"email":24},"Dheeraj Kodali, MD",{"facility":88,"status":52,"city":89,"state":90,"zip":91,"country":56,"countryCode":57,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Fort Wayne Medical Oncology and Hematology","Fort Wayne","Indiana","46804",{"type":59,"coordinates":93},[94,95],-85.12886,41.1306,{"lat":95,"lon":94},[98,101],{"name":99,"role":46,"phone":24,"phoneExt":24,"email":100},"Phil Huston","phil.hutson@fwmoh.com",{"name":102,"role":70,"phone":24,"phoneExt":24,"email":24},"Sunil Babu, MD",{"facility":104,"status":52,"city":105,"state":106,"zip":107,"country":56,"countryCode":57,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"New Mexico Cancer Center","Albuquerque","New Mexico","87109",{"type":59,"coordinates":109},[110,111],-106.65114,35.08449,{"lat":111,"lon":110},[114,117],{"name":115,"role":46,"phone":24,"phoneExt":24,"email":116},"Valerie Tucker","valeriet@nmohc.com",{"name":118,"role":70,"phone":24,"phoneExt":24,"email":24},"Katherine Sanchez, MD",{"facility":120,"status":52,"city":121,"state":122,"zip":123,"country":56,"countryCode":57,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Oklahoma Cancer Specialists and Research Institute","Tulsa","Oklahoma","74146",{"type":59,"coordinates":125},[126,127],-95.99277,36.15398,{"lat":127,"lon":126},[130,133],{"name":131,"role":46,"phone":24,"phoneExt":24,"email":132},"Ruth Dunn","ruth.dunn@ocsri.org",{"name":134,"role":70,"phone":24,"phoneExt":24,"email":24},"Paul Zito, MD",{"facility":136,"status":52,"city":137,"state":138,"zip":139,"country":56,"countryCode":57,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"Oncology Consultants","Houston","Texas","77030",{"type":59,"coordinates":141},[142,143],-95.36327,29.76328,{"lat":143,"lon":142},[146,149],{"name":147,"role":46,"phone":24,"phoneExt":24,"email":148},"Laura Guerra","lguerra@OncologyConsultants.com",{"name":150,"role":70,"phone":24,"phoneExt":24,"email":24},"Julio Peguero, MD",{"facility":152,"status":52,"city":153,"state":154,"zip":155,"country":56,"countryCode":57,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"Northwest Medical Specialities","Puyallup","Washington","98373",{"type":59,"coordinates":157},[158,159],-122.2929,47.18538,{"lat":159,"lon":158},[162,165],{"name":163,"role":46,"phone":24,"phoneExt":24,"email":164},"Malee Chhan","mchhan@nwmsonline.com",{"name":166,"role":70,"phone":24,"phoneExt":24,"email":24},"Sibel Blau, MD",{"type":168,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[170],{"name":171,"class":172},"Exigent","UNKNOWN","100537056",false,"NCT06272864","BostonGene and Exigent Genomic INsight Study","BostonGene and Exigent Genomic INsight (BEGIN) Study: A Prospective Study of Comprehensive Molecular Testing in Advanced Cancer Patients in the Community Setting","BEGIN","Inclusion Criteria:\n\n* Patients must have a confirmed malignancy of:\n\nLocally recurrent, unresectable, or metastatic breast cancer or; Unresectable stage III or metastatic non-small cell lung cancer or; Unresectable or metastatic melanoma or; Locally advanced or metastatic l sarcoma.\n\n* Life expectancy \\> 3 months as per the treating physician\n* Willingness to provide informed consent\n* Living in the United States at time of enrollment\n* Agree to participate in genomic and molecular profiling\n\nExclusion Criteria:\n\n* not meeting the inclusion criteria","ALL","18 Years",{"count":183,"type":184},400,"ESTIMATED","2 Years","OBSERVATIONAL","The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical trials. Four cohorts of 100 patients each will be studied over two years, focusing on treatment decisions and patient outcomes. This study seeks to demonstrate the clinical utility of genomic testing in guiding therapy for advanced cancer patients in community settings.",[189,190,38,41],"Breast Cancer","Non-small Cell Lung Cancer",[192,193,194,195],"Comprehensive Molecular Testing","BostonGene Tumor Portrait Test","Molecularly Matched Therapy","DNA and RNA Targets","2025-02-14",{"date":198,"type":199},"2025-02-17","ACTUAL",{"date":201,"type":199},"2024-04-08",{"date":203,"type":184},"2028-01-08",{"name":5,"class":6},7]